Hoffmann-La Roche: Macular Degeneration trials

The registry lists 32 Macular Degeneration studies with Hoffmann-La Roche as lead sponsor. 3 are open to participants now and 11 have results posted.

Phase 1 5Phase 2 8Phase 3 14Phase 4 2No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationRecruitingNCT07851259Phase 2
• A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMDRecruitingNCT06847542Phase 3
• Extension Study for the Port Delivery System With Ranibizumab (Portal)RecruitingNCT03683251Phase 3
• A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled SyringeCompletedNCT05569148Phase 3Results posted
• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular DegenerationCompletedNCT04777201Phase 3Results posted
• A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationTerminatedNCT04607148Phase 2Results posted
• A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)TerminatedNCT03972709Phase 2Results posted
• A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular DegenerationCompletedNCT03677934Phase 3Results posted
• Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular DegenerationCompletedNCT03038880Phase 2Results posted
• Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular DegenerationCompletedNCT02510794Phase 2Results posted
• Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular DegenerationActive, not recruitingNCT02286089Phase 1/2Results posted
• An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)CompletedNCT01442064Not applicableResults posted
• A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)CompletedNCT00891735Phase 3Results posted
• An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVOCompletedNCT00379795Not applicableResults posted
• A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)TerminatedNCT06961370Phase 1
• A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular DegenerationActive, not recruitingNCT06795048Phase 4
• A Study Conducted to Evaluate the Conjunctiva and Tenon's Capsule Status of Healthy Subjects and in Participants With Neovascular Age-related Macular Degeneration (nAMD)/Diabetic Macular Edema (DME)CompletedNCT06723288
• A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)Active, not recruitingNCT06680817
• A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)Active, not recruitingNCT05562947Phase 3
• An Observational Study of the Progression of Intermediate Age-Related Macular DegenerationActive, not recruitingNCT05300724
• A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular DegenerationWithdrawnNCT05126966Phase 3
• A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)Active, not recruitingNCT04853251Phase 4
• A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)Active, not recruitingNCT04657289Phase 3
• Study of Zifibancimig in Participants With Neovascular Age-related Macular DegenerationCompletedNCT04567303Phase 1/2
• Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®)CompletedNCT02420132
• A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular DegenerationCompletedNCT01941082Phase 1
• A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)CompletedNCT00251459Phase 3
• Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)CompletedNCT00095433Phase 3
• A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)CompletedNCT00090623Phase 3
• A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular DegenerationCompletedNCT00061594Phase 3
• A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular DegenerationCompletedNCT00056836Phase 3
• Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)CompletedNCT00056823Phase 1/2